Efficacy and safety of benralizumab

The purpose of the review is to analyze Russian and foreign literature sources on the effectiveness and safety of benralizumab in the treatment of moderate and severe bronchial asthma. Benralizumab is a humanized monoclonal antibody directed against the interleukin-5 receptor (IL-5R) subunit. Binding of benralizumab with the alpha chain of IL-5R leads to inhibition of hetero-oligomerization of alpha and beta subunits, thus preventing signal transduction and consequent proliferation of eosinophils and basophils and the cascade of events following it. Benralizumab significantly reduces annual asthma exacerbation rates and is well tolerated by patients with severe uncontrolled asthma. The efficacy and long-term adverse reactions of benralizumab therapy have not been sufficiently studied and require more detailed analysis.